Moderna (MRNA) Cash & Equivalents (2017 - 2026)

Moderna (MRNA) has reported Cash & Equivalents for 10 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 34.71% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 34.71% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, up 34.67% from the prior year.
• Cash & Equivalents was $1.7 billion for Q2 2026 at Moderna, down from $1.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.0 billion in Q1 2022 and troughed at $1.1 billion in Q3 2025.
• A 5-year average of $2.5 billion and a median of $2.5 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 53.2% in 2022 and surged 34.71% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $3.2 billion in 2022, then declined by 9.3% to $2.9 billion in 2023, then slumped by 33.71% to $1.9 billion in 2024, then surged by 34.67% to $2.6 billion in 2025, then plunged by 33.6% to $1.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.7 billion (Q2 2026), $1.9 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.